Gastrointestinal Symptoms: The second most frequent category of adverse events involved digestive system effects
This signals satiety (feeling full), slows gastric emptying (so food stays in the stomach for longer), reduces cravings and reward-driven eating, enhances insulin sensitivity, and lowers blood sugar spikes
In 2025, the European Medicines Agency concluded that NAION should be listed as a very rare side effect of semaglutide medications, including Ozempic, Wegovy, and Rybelsus, after reviewing clinical studies, adverse event reports, and post-market safety data
GLP-1 therapy is FDA-approved for chronic weight management in people with overweight and obesity, with safety data supporting years of continuous use
Growth differentiation factor-15 and its role in diabetes and cardiovascular disease
Gut health is heavily intertwined with nutritional status